Heartflow, INC Form 4 insider transactions

NASDAQ
Heartflow's Chief Accounting Officer, Marie L. Jones, disposed of 81 common shares to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
HealthCor Partners entities plan to convert significant preferred stock and convertible notes into Heartflow common stock by August 2025.
NASDAQ
Bain Capital Life Sciences entities converted Series F Preferred Stock and a Subordinated Convertible Promissory Note into Heartflow, Inc. common stock.
NASDAQ
Heartflow, Inc. Director Julie A. Cullivan was granted 23,710 stock options with an exercise price of $19, vesting over one year.
NASDAQ
Heartflow Director William C. Weldon acquired 136,286 common shares through preferred stock conversions and was granted 23,710 stock options.
NASDAQ
Heartflow, Inc. Director Wayne Joseph Riley was granted 23,710 stock options with an exercise price of $19, set to vest by August 2026.
NASDAQ
Heartflow, Inc. CEO John C.M. Farquhar received grants of 59,868 restricted stock units and options for 314,603 shares of common stock.
NASDAQ
Heartflow's Chief Financial Officer, Vikram Verghese, reported the acquisition of restricted stock units and stock options, alongside the conversion of a promissory note into common stock.
NASDAQ
Heartflow's Chief Medical Officer, Campbell Rogers, was granted 21,052 Restricted Stock Units and 110,629 stock options, vesting over several years.
NASDAQ
Heartflow's Chief Accounting Officer, Marie L. Jones, reported the acquisition of restricted stock units, stock options, and the conversion of promissory notes into common stock.
NASDAQ
Heartflow Director Timothy C. Barabe converted convertible promissory notes into common stock and was granted new stock options.
NASDAQ
Heartflow, Inc. Director Casey M. Tansey reported the conversion of various preferred stock and convertible notes into common stock and the grant of new stock options.
NASDAQ
Heartflow Director Jeffrey C. Lightcap increased his beneficial ownership through the conversion of preferred stock and convertible notes into common stock, and the grant of new stock options.